“The Right Approach” To Regulating Biomarkers: An Interview With Interleukin Genetics CEO Lewis Bender (Part 3)
This article was originally published in The Pink Sheet Daily
Executive Summary
Setting standards in an emerging area of science is a big challenge, both for FDA and regulated industry. One diagnostics CEO thinks FDA is taking an appropriately careful approach.